

## Agenda

<b>Title of Meeting</b>	Somerset Prescribing Forum
<b>Date</b>	17 <sup>th</sup> January 2018
<b>Time</b>	14.30
<b>Venue</b>	Meeting Room 2, Wynford House, Yeovil BA22 8HR

Please notify Catherine Henley if you are unable to attend at:

Agenda Number	Item Description and Action	Item Presenter / Details of Enclosed Papers
<b>1</b>	<b>Introductions:</b>	
	Donna Yell and Michaela Nock	
<b>2</b>	<b>Apologies for absence:</b>	
	Andrew Prowse and Orla Dunn	
<b>3</b>	<b>Declarations of interest</b>	See last page of agenda
<b>4</b>	Minutes of the meeting on 15 <sup>th</sup> November 2017	Attachment 4
	• Review of action points	
	<b>PART 1 – Items for discussion or decision</b>	
<b>5</b>	<b>Matters Arising</b>	
5.1	Antipsychotics in learning difficulties- SomPar Audit Data	To be tabled- if ready
5.2	SomPar request for dual use of cholinesterase inhibitors and memantine	<a href="#">NICE Draft guidance consultation</a>
5.3	Amended DVT Pathway	Attachment 5.3
5.4	LMWH Bridging Guidance –YDH update	To be tabled- if ready
5.5	Draft Single Shared Care Guideline for DMARDs	<b>Attachment 5.5</b>
<b>6</b>	<b>Other Issues</b>	
6.1	Managing prescribable items of low priority for NHS funding	Attachment s 6.1 a &b
6.2	Falsified Medicines Directive	Attachment 6.2
6.3	<b>RPC- National Early Warning Score chart</b>	<b>Attachment 6.3</b>
6.4	Use of licensed medicines for unlicensed applications in psychiatric practice	Attachment 6.4
<b>7</b>	<b>Formulary Applications</b>	
7.1	<a href="#">Trelegy Ellipta</a> <sup>®</sup> inhalation powder pre-dispensed (Fluticasone furoate 92mcg/ Umeclidinium 55mcg/ Vilanterol 22mcg) 1x 30 dose £44.50 (GlaxoSmithKline UK) Is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist.	See Link

7.2	<p>Delmosart® (methylphenidate) Prolonged Release Tablets  <a href="#">18mg x 30 £15.59</a>; <a href="#">27mg x 30 £18.41</a>; <a href="#">36mg x 30 £21.23</a>; <a href="#">54mg x 30 £36.81</a> (Accord)</p> <p>Is indicated as part of a comprehensive treatment programme for ADHD in children aged 6 years of age and over when remedial measures alone prove insufficient. Treatment must be under the supervision of a specialist in childhood behavioural disorders.</p>	See Link
7.3	<p>Desitrend® (Levetiracetam) granules in sachets minitables  <a href="#">60x 250mg £22.41</a>; <a href="#">60x 500mg £39.46</a>; <a href="#">60x 1000mg £76.27</a>; (Desitin Pharma Ltd)</p> <p>Is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy.</p> <p>Is indicated as adjunctive therapy:</p> <ul style="list-style-type: none"> <li>• In the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents, children and infants from 1 month of age with epilepsy.</li> <li>• In the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.</li> <li>• In the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.</li> </ul>	Attachment 7.3
<b>8</b>	<b>DTC decisions and other reports</b>	
8.1	Somerset Partnership D&TC – Last meeting 05/12/17- updated action points 5/12/17	To be tabled
8.2	YDH D&TC – Last meeting 22/11/17 cancelled – no new minutes	
8.3	T&ST D&TC – Last meeting 10/11/17- Minutes not received	To be tabled
8.4	T&S Antimicrobial Prescribing Group - Last meeting 08/11/2017- minutes received.	To be tabled
8.5	RUH Bath D&TC – Last meeting (9/11/17,-cancelled) 14/12/17 – Minutes not received	To be tabled
8.6	BNSSG D&TC – Last meetings 20/09/2017, 29/11/17 – Minutes received	To be tabled
8.7	BNSSG Joint Formulary Group –previous meetings- Last meetings 05/09/17, 17/10/17, 28/11/17 – Minutes received	To be tabled
8.8	LPC report	Michael Lennox
	<b>Part 2 – Items for Information or Noting</b>	
<b>9</b>	<b>NICE Guidance (see <a href="#">December link</a> and <a href="#">January link</a> for guidance by month)</b>	See Link
	<b>NICE Technology Appraisals</b>	
9.1	<a href="#">TA492 Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable</a> <b>For noting</b>	See Link
9.2	<a href="#">TA493 Cladribine tablets for treating relapsing–remitting multiple sclerosis</a> <b>For noting</b>	See Link
9.3	<a href="#">TA494 Naltrexone–bupropion for managing overweight and obesity</a> – <b>Negative appraisal for noting</b>	See Link
9.4	<a href="#">TA495 Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer</a> <b>For noting</b>	See Link

9.5	<a href="#">TA496 Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer</a> <b>For noting</b>	See Link
9.6	<a href="#">TA497 Golimumab for treating non-radiographic axial spondyloarthritis</a> - <b>For noting</b>	See Link
<b>10</b>	<b>NICE Clinical Guidance</b>	
10.1	<a href="#">NG80 Asthma: diagnosis, monitoring and chronic asthma management</a>	<a href="#">BMJ key differences</a>
10.2	<a href="#">NG81: Fractures (complex): assessment and management</a> <b>Update November 2017</b> amended recommendation 1.1.10 to change the wording from 'administer prophylactic antibiotics' to 'consider administering prophylactic antibiotics'.	See Link
10.3	<a href="#">CG71 Familial hypercholesterolaemia: identification and management</a> – <b>Update November 2017</b> reviewed the evidence for case finding and diagnosis, identification using cascade testing, and management using statins. We amended recommendations in sections 1.1, 1.2 and 1.3.	See Link
10.4	<a href="#">CG128 Autism spectrum disorder in under 19s: recognition, referral and diagnosis</a> – <b>Update December 2017</b> , NICE reviewed the evidence and added ADHD as a factor associated with an increased prevalence of autism and changed references from DSM-4 to DSM-5.	See Link
10.5	<a href="#">QS124 Suspected cancer</a> - <b>Update December 2017</b> , the source guidance and definitions for statement 3 were amended to reflect the NICE diagnostics guidance on quantitative faecal immunochemical tests to guide referral for colorectal cancer in primary care.	See Link
<b>11</b>	<b>Specialist Commissioning</b>	
11.1	Specialised Commissioning Drugs Briefing: Autumn 2017	Attachment 11.1
<b>12</b>	<b>PBR excluded drug monitoring</b>	
12.1	T & S	To be tabled
12.2	Yeovil	To be tabled
<b>13</b>	<b>Horizon Scanning</b>	
13.1	<a href="#">NICE forward planner</a> - <b>for noting</b>	See Link
<b>14</b>	<b>Safety items, NPSA Alerts and Signals</b>	
14.1	<a href="#">MHRA November drug safety update</a> and <a href="#">MHRA December drug safety update</a> and <a href="#">MHRA January drug safety update</a>	See Links
14.2	Patient Safety alert: <a href="#">Confirming removal or flushing of lines and cannulae after procedures</a>	See Link
<b>15</b>	<b>BNF Changes</b>	
	BNF Update <a href="#">November</a> and <a href="#">December</a>	See Link
<b>16</b>	<b>Any other business</b>	
	<b>Date of Next Meetings:</b>	
	Wednesday 14 <sup>th</sup> March 2018	MR2, Wynford House
	Wednesday 23 <sup>rd</sup> May 2018	MR1, Wynford House
	Wednesday 18 <sup>th</sup> July 2018	MR2, Wynford House

**Distribution (as of January 2018)**

Dr Clare Barlow  
Jon Beard  
Dr Rosemary Brook  
Steve Du Bois  
Orla Dunn  
Shaun Green

Catherine Henley  
Michael Lennox  
Sam Morris  
Dr Robert Munro  
Michaela Nock  
Jean Perry

Andrew Prowse  
Dr Geoff Sharp  
Zoe Talbot-White  
Donna Yell

**For Information**

██████████

████████████████

██████████████

██████████████

██████████

██████████████

████████████████

██████████

██████████████

██████████

Karen Taylor

████████████████████

**Somerset CCG Prescribing Forum – Declaration of Interests (September 2017)**

Name	Position	Interests Declared
Dr Clare Barlow	Chair, Drug & Therapeutics Committee, Taunton & Somerset NHS Foundation Trust	Occasional sponsored educational meetings.
Jon Beard	Chief Pharmacist, Taunton & Somerset NHS Foundation Trust	None declared
Steve DuBois	Somerset Partnership Chief Pharmacist	Employee of Somerset Partnership NHS Foundation Trust Pharmacy Management network team member. Lister House Surgery management has been taken over by Somerset Partnership. 3/17 - Took part in a group to develop a pharmacy education programme on Diabetes, it had no promotional content but was funded by the Novo Nordisk.
Dr Orla Dunn	Consultant, Public Health, Somerset County Council	Director and part owner of Health Behaviour Research Ltd Partner is director of Power System Consulting Ltd
Shaun Green	Head of Medicines Management	16/17 none declared
Liz Harewood	Somerset Partnership Representative	Occasional attendance at pharmaceutical industry supported meetings & training. Will advise if related to any medicine under discussion.
Catherine Henley	Medicines Manager, NHS Somerset CCG	Practice Pharmacist at Wellington Medical Centre and Work as a locum community pharmacist. Ad hoc Consultancy work 17/12/15 NHIS Virtual Advisory Board on the treatment of depression. -Sponsored by Lundbeck
Ann Lee	St Margaret's Hospice	None declared

Michael Lennox	LPC Representative	Chief Officer Somerset LPC Head of Operations Clinical Pharmacy Services Livewell Southwest (CIC NHS community and mental health provider across South Devon) Director of Lennox Health Partnerships (ad hoc consultancy) Pending joining of council of National association of Primary care as a representative for community pharmacy
Sam Morris	Medicines Manager, NHS Somerset CCG	Zero hour contract pharmacist for Boots.
Dr Robert Munro	LMC Representative	GP Partner Ryalls Park Medical Centre, Provides Out-of-Hours services for Somerset Doctors and Urgent Care (SDUC) Member of Somerset Primary Healthcare
Michaela Nock	Deputy Clinical Pharmacy Manager, Yeovil NHS Foundation Trust	Occasional lunchtime meetings sponsored by pharmaceutical companies providing lunch
Jean Perry	Commissioning Manager, NHS Somerset CCG	None declared
Andrew Prowse	Chief Pharmacist, Yeovil NHS Foundation Trust	Chief Pharmacist, Dorset county hospital NHS Foundation Trust
Dr Geoff Sharp	Chair	GP Partner, The Park Medical Partnership, PMS Practice Somerset CCG Governing Body GP The Park Medical Practice is a provider of medical services to Shepton Mallet Community Hospital (under contract to Somerset Partnership NHS Foundation Trust) Provides Out-of-Hours services for Somerset Doctors and Urgent Care (SDUC) Member of Somerset Primary Healthcare
Zoe Talbot-White	Prescribing Support Technician, Somerset CCG	None declared
Stephanie Wadham	Senior Pharmacist, Yeovil NHS FT	None declared
Donna Yell	Pharmacoeconomic s Lead, Yeovil NHS Foundation Trust	Occasional lunchtime meetings sponsored by pharmaceutical companies providing lunch. Occasional meetings with reps to discuss new medicines.